RENB.Renovaro INC
10-Q: Renovaro Inc. Reports Q2 2024 Results, Focuses on Oncology Pipeline
Sentiment:
Quarterly Report
Renovaro Inc. reports a net loss for the second quarter of 2024, while highlighting progress in its oncology and HIV therapeutic programs.
Capital raiseThe company intends to attempt to secure additional required funding through equity or debt financing.The company may raise funds through public or private sales of its equity or debt securities.
Worse than expectedThe company reported a net loss of $4.53 million for the quarter and $13.7 million for the six-month period, which is worse than the previous period.The company's cash balance is low at $243,980, and it has a working capital deficit of $11.36 million, indicating a worsening financial position.
Summary
- Renovaro Inc. reported a net loss of $4.53 million for the three months ended December 31, 2023, and a net loss of $13.7 million for the six months ended December 31, 2023.
- The company's operating expenses totaled $4.27 million for the quarter and $13.15 million for the six-month period.
- General and administrative expenses were $3.62 million for the quarter and $11.91 million for the six-month period, while research and development expenses were $0.62 million for the quarter and $1.19 million for the six-month period.
- The company's cash balance stood at $243,980 as of December 31, 2023, with a working capital deficit of $11.36 million.
- Renovaro is focusing on its oncology platform, particularly the RENB-DC11 program for pancreatic cancer, and is aiming to begin clinical trials in the second half of 2024.
- The company has also made progress in its HIV therapeutic vaccine program, RENB-HV12, with non-human primate studies ongoing.
- Renovaro completed the acquisition of GEDi Cube Intl Ltd. on February 13, 2024, making it a wholly-owned subsidiary.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While there is progress in the company's pipeline and a strategic acquisition, the significant net losses, low cash balance, and going concern warning raise concerns. The company's financial position is weak, and it is dependent on raising additional capital.
Positives
- The company is making progress in its oncology program, RENB-DC11, with promising pre-clinical results and plans to start clinical trials in the second half of 2024.
- The HIV therapeutic vaccine program, RENB-HV12, is advancing with ongoing non-human primate studies.
- The acquisition of GEDi Cube Intl Ltd. was completed, potentially adding value to the company.
- The company has streamlined its organization to focus on oncology and HIV therapies.
Negatives
- The company reported a net loss of $4.53 million for the quarter and $13.7 million for the six-month period.
- Renovaro has a low cash balance of $243,980 as of December 31, 2023.
- The company has a working capital deficit of $11.36 million.
- There is substantial doubt about the company's ability to continue as a going concern for one year after the date the financial statements are issued.
- The company has identified a material weakness in controls over financial reporting.
Risks
- The company's ability to continue as a going concern is dependent on obtaining additional financing and achieving FDA approval for its product candidates.
- The company has a history of losses and may not achieve profitability.
- There is a risk of significant dilution to stockholders if the company raises capital through equity financing.
- The company is involved in multiple legal proceedings, which could adversely affect its liquidity and financial position.
- The company has identified a material weakness in its internal controls over financial reporting.
Future Outlook
The company plans to focus on its oncology platform, particularly the RENB-DC11 program, and aims to begin clinical trials in the second half of 2024. The company also intends to secure additional funding through equity or debt financing.
Management Comments
- Management has reduced overhead and administrative costs by streamlining the organization to focus around two of its therapies (oncology and a HIV therapeutic vaccine).
- The Company has tailored its workforce to focus on these therapies.
- The Company intends to attempt to secure additional required funding through equity or debt financing.
Industry Context
The company operates in the competitive biotechnology industry, focusing on advanced cell and gene therapies for cancer and infectious diseases. The company's approach of using allogeneic cells and genetic modifications aligns with current trends in immunotherapy and personalized medicine.
Comparison to Industry Standards
- The company's cash burn rate and net losses are typical for pre-revenue biotechnology companies in the clinical development stage.
- The focus on allogeneic cell therapies is a growing trend in the industry, with companies like Allogene Therapeutics and Fate Therapeutics also pursuing similar approaches.
- The company's approach to pancreatic cancer treatment is in line with the industry's focus on developing novel therapies for difficult-to-treat cancers.
- The company's HIV therapeutic vaccine program is competing with other companies and research institutions working on similar approaches, such as Gilead Sciences and the NIH.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Board of Directors | NA | Avram Miller | 2023-10-11 | To fill a vacancy |
Legal Proceedings
- The company is involved in multiple legal proceedings, including securities class action litigation, federal derivative litigation, and state derivative litigation.
- The company has filed a complaint against Serhat Gmrkc, et al., alleging a scheme to falsify study results.
- The company is defending against a claim of malicious prosecution by its former CFO.
- The company is defending against claims of breach of an Investor Rights Agreement.
Related Party Transactions
- The company entered into a promissory note agreement with RS Bio ApS, a related party.
- RS Bio ApS purchased units in the company's private placement.
- Paseco ApS converted a promissory note and purchased units in the company's private placement.
- The company has a consulting agreement with Paseco ApS.
- The company issued restricted common shares to Paseco ApS in lieu of services.
- The company entered into an advisory agreement with Avram Miller, a director, and issued restricted stock as compensation.
Stakeholder Impact
- Shareholders face the risk of significant dilution if the company raises capital through equity financing.
- Employees may be affected by the company's cost-cutting measures and potential restructuring.
- Customers and partners may be impacted by the company's financial instability and potential delays in product development.
- Creditors face the risk of non-payment if the company is unable to secure additional funding.
Next Steps
- The company plans to complete IND-enabling activities for RENB-DC11 in the second half of 2024.
- The company aims to start clinical trials for RENB-DC11 in the second half of 2024.
- The company will continue non-human primate studies for RENB-HV12.
- The company will work to integrate GEDi Cube as a wholly-owned subsidiary.
- The company will seek additional funding through equity or debt financing.
Key Dates
| Date | Description |
|---|---|
| 2011-01-18 | Company incorporated as Putnam Hills Corp. |
| 2014-02-06 | Board adopted the Companys 2014 Equity Incentive Plan |
| 2017-11-13 | Renovaro entered into a Lease Agreement for a term of five years and two months |
| 2018-06-19 | Renovaro entered into a Lease Agreement for a term of ten years |
| 2018-07-09 | Company entered into a consulting agreement with G-Tech Bio, LLC |
| 2019-11-15 | Company entered into a Framework Agreement with G-Tech and SRI |
| 2020-01-31 | Company entered into a Statement of Work and License Agreement (HBV License Agreement) |
| 2020-02-06 | Company issued two Convertible Notes to Paseco ApS |
| 2020-03-30 | Company issued a Promissory Note in the principal amount of $5,000,000 |
| 2021-08-25 | Company entered into an ALC Patent License and Research Funding Agreement |
| 2021-09-10 | Company paid the initial payment of $600,000 for the ALC License Agreement |
| 2022-06-20 | Company entered into a sublease Agreement with One Health Labs |
| 2022-07-26 | Securities class action complaint (Chow Action) filed against the Company |
| 2022-07-28 | Securities class action complaint (Manici Action) filed against the Company |
| 2022-09-22 | Samuel E. Koenig filed a shareholder derivative action |
| 2022-10-20 | Susan Midler filed a shareholder derivative action |
| 2022-10-21 | Company filed a Complaint against Serhat Gmrkc, et al. |
| 2022-12-30 | Company amended and restated the Convertible Notes |
| 2023-04-18 | Company entered into a sublease termination agreement |
| 2023-06-20 | Company entered into a purchase agreement with Lincoln Park Capital |
| 2023-06-26 | Holder of Convertible Notes elected to exercise conversion right |
| 2023-07-21 | Company adopted the Renovaro Biosciences Inc. 2023 Equity Incentive Plan |
| 2023-07-31 | Company and Holder agreed to amend the Promissory Note (Fourth Amendment) |
| 2023-08-01 | Company closed a private placement of 280,505 units |
| 2023-08-11 | Company entered into a Promissory Note (Notes Receivable) in the amount of $550,000 |
| 2023-08-18 | Company entered into a Promissory Note (Notes Receivable) in the amount of $500,000 |
| 2023-09-28 | Company entered into a Stock Purchase Agreement with GEDi Cube Intl Ltd. |
| 2023-10-05 | Company entered into Subscription Agreements to purchase 5% Original Issue Discount Convertible Promissory Notes |
| 2023-10-11 | Avram Miller appointed to the Board of Directors |
| 2023-11-03 | Company entered into an agreement to purchase 5% Original Issue Discount Promissory Note for $1,000,000 |
| 2023-11-30 | Company entered into a premium finance agreement |
| 2023-11-30 | Company and the Holder agreed to amend the Promissory Note (Fifth Amendment) |
| 2023-12-29 | Company entered into Subscription Agreements to purchase Convertible Promissory Notes for $560,000 |
| 2024-01-01 | Company entered into an amendment with RS Bio for the $1,000,000 Note Payable bridge loan |
| 2024-01-02 | Company entered into an agreement with RS Bio to purchase a 5% Original Issue Discount Secured Promissory Note for $526,315 |
| 2024-01-11 | Company entered into an amendment with one of the investors of the 2023 Notes |
| 2024-01-11 | Company entered into a Subscription Agreement to purchase a Convertible Promissory Note for $460,000 |
| 2024-01-12 | Company entered into Subscription Agreements to purchase Convertible Promissory Notes for $125,000 |
| 2024-01-23 | Weird Science and Wittekind filed a shareholder derivative action |
| 2024-01-24 | Company entered into a Promissory Note (Notes Receivable) in the amount of $143,000 |
| 2024-01-25 | Shareholders of Renovaro approved the issuance of Renovaro Shares in connection with the Transaction |
| 2024-02-01 | Company filed a Certificate of Amendment of Certificate of Incorporation |
| 2024-02-05 | Company entered into an agreement with RS Bio to purchase a 5% Original Issue Discount Secured Promissory Note for $105,263 |
| 2024-02-12 | Company entered into amendments with GEDi Loans related to the Notes Receivable |
| 2024-02-13 | Company consummated the acquisition of GEDi Cube and changed its corporate name to Renovaro Inc. |
| 2024-02-14 | Date of the filing of the 10-Q report |
Keywords
oncology, HIV, gene therapy, cell therapy, clinical trials, biotechnology, RENB-DC11, RENB-HV12, GEDi Cube, financial results
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.